ICCC Q2 2025 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+17.8% YoY

Gross Profit

$3M43.7% margin

Operating Income

$569,5628.8% margin

Net Income

$501,8807.8% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

-20.1%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$66,714

Balance Sheet

Total Assets

$47M

Total Liabilities

$17M

Stockholders' Equity

$30M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$5M	+17.8%
Gross Profit	$3M	$1M	+129.0%
Operating Income	$569,562	-$1M	+141.1%
Net Income	$501,880	-$2M	+132.8%

Geographic Segments

UNITED STATES

$5M100%